EHA2024
Were you unable to connect with us at EHA2024 Hybrid Congress?
If so, please contact us here. Our team will be pleased to talk to you through our congress activities and answer any queries you may have.
Did you miss our BeiGene-sponsored Satellite Symposia?
If so, slides and webcasts of both symposia are available on our website. See below for details.
Satellite Symposium: ‘The data behind your treatment selection in CLL & indolent lymphomas’
Chaired by Prof. Wendtner, this first satellite symposium provided insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The experts discussed their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) were also presented. You can download the slides and view the webcast here.
Satellite Symposium: ‘All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment’
In the second satellite symposium, a panel of hematology experts chaired by Prof. Stilgenbauer, discussed topics such as an introduction to BTKis for CLL in clinical practice, resistance mutations and BTKi switching, the safety profile of BTKis and management of cardiovascular events, and pharmacokinetics and pharmacodynamics of BTKis. The slides and webcast are available here.
Product Theater: ‘Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL’
At this promotional event, Dr. Scarfò presented evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
Learn more about BeiGene here.
0524-BRU-PRC-178